RxSight Q4 revenue $8.4M (+71% YoY); FY22 guidance $40-44M

RxSight, Inc.

Q4 2021 revenue $8.4M, up 71% YoY; FY2021 revenue $22.6M, up 54% YoY.
Q4 net loss $(15.7)M ($(0.58)/diluted share); adjusted net loss $(12.8)M ($(0.47)/share).
Sold 45 LDDs in Q4, installed base 206; 2,959 LALs sold in Q4.
Cash and investments $159.3M; long-term debt $39.8M as of Dec 31, 2021.
FY2022 revenue expected $40-44M; gross margin 35-36%; OpEx $86-90M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.